MedTrace Logo

Colchicine in ST-elevation Myocardial Infarction

NCT01936285 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2015-04-23

No results posted yet for this study

Summary

* There is evidence that inflammatory processes may play detrimental role during the acute phase of myocardial infarction
* The hypothesis of this study is that colchicine, by its anti-inflammatory action, may lead to reduction in infarct size, when administered during the acute phase of myocardial infarction

Conditions

  • Acute Myocardial Infarction

Interventions

DRUG

Colchicine 2 mg loading dose; 0.5 mg bid for 5 days

DRUG

Placebo

Sponsors & Collaborators

  • G.Gennimatas General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-04-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01936285 on ClinicalTrials.gov